PDLI
$3.37
Pdl Biopharma
$.01
.30%
PDLI
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $0.05
Revenue:  $0.00 Mil
Thursday
Mar 12
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, November 6, 2019

What do you expect when PDLI reports earnings?
Beat
Meet
Miss

Where is PDLI's stock price going from here?
Up
Flat
Down
Stock chart of PDLI
Analysts
Summary of analysts' recommendations for PDLI
Score
Grade
Pivots
Resistance
$3.56
$3.51
$3.43

$3.38

Support
$3.30
$3.25
$3.17
Tweet
Growth
Description
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsInterCeptZoetisJohnson & JohnsonMylanUltragenyx PharmaceuticalBristol-Myers SquibbAlkermes